📦 Product details
| Product Name |
Tirzepatide |
| Purity |
over 98% |
| Shelf Life |
3 years |
| Payment ways |
Western Union, bank transfer or Bitcoin |
| Shipping Time |
Normally need take around 7-15 days |
| Delivery |
Delivery after receive the payment |
Tirzepatide is a new type of drug for the treatment of type 2 diabetes, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is unique in that it combines the dual effects of a GLP-1 receptor agonist and an insulin receptor agonist, resulting in a more effective reduction in blood sugar levels and weight.
Tirzepatide promotes insulin secretion, inhibits glucagon secretion, and slows down the emptying rate of the gastrointestinal tract by activating GLP-1 receptors, thereby reducing postprandial blood sugar peaks and fasting blood sugar levels. At the same time, it also increases tissue sensitivity to insulin by activating insulin receptors, promoting glucose uptake and utilization, thereby further reducing blood sugar levels.
Clinical trials have shown that Tirzepatide has a stronger hypoglycemic effect and a more significant weight loss effect compared to other GLP-1 receptor agonists. In addition, it has been shown to improve patients’ insulin resistance, reduce insulin use, reduce the risk of hypoglycemia, and have a positive impact on cardiovascular health.
Tirzepatide is dosed as a once-weekly subcutaneous injection and can be administered at any time point, regardless of meal times. It can be used as a monotherapy or in combination with other oral hypoglycemic drugs and is suitable for blood sugar control in patients with type 2 diabetes.
In summary, Tirzepatide, as a new type of GLP-1 receptor agonist, has stronger hypoglycemic effect, more significant weight loss effect and better cardiovascular protection effect, and can provide treatment for patients with type 2 diabetes. More effective treatment options.
